Literature DB >> 25572666

Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series.

Hubert Y Pan1, Shengpeng Jiang2, Jordan Sutton1, Zhongxing Liao1, William W Chance1, Steven J Frank1, X Ronald Zhu3, Heng Li3, Hiral P Fontanilla1, Xiaodong Zhang3, Daniel R Gomez4.   

Abstract

PURPOSE: The purpose of this study was to describe our experience implementing intensity modulated proton therapy (IMPT) for lung-intact malignant pleural mesothelioma (MPM), including patient selection, treatment planning, dose verification, and process optimization. METHODS AND MATERIALS: Seven patients with epithelioid MPM were reviewed; 6 underwent pleurectomy, whereas 1 had biopsy alone. Four patients received IMPT and 3 received intensity modulated radiation therapy. Treatment plans for the other modality were created for dosimetric comparisons. Quality assurance processes included dose verification and robustness analysis. Image-guided setup was performed with the first isocenter, and couch shifts were applied to reposition to the second isocenter.
RESULTS: Treatment with IMPT was well tolerated and completed without breaks. IMPT plans were designed with 2 isocenters, 4 beams, and ≤64 energy layers per beam. Dose verification processes were completed in 3 hours. Total daily treatment time was approximately 45 minutes (20 minutes for setup and 25 minutes for delivery). IMPT produced lower mean doses to the contralateral lung, heart, esophagus, liver, and ipsilateral kidney, with increased contralateral lung sparing when mediastinal boost was required for nodal disease.
CONCLUSIONS: Our initial experience showed that IMPT was feasible for routine care of patients with lung-intact MPM.
Copyright © 2015 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25572666     DOI: 10.1016/j.prro.2014.11.005

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  11 in total

Review 1.  Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma.

Authors:  Gwendolyn Cramer; Charles B Simone; Theresa M Busch; Keith A Cengel
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  [Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline].

Authors:  Christoph Süß; Oliver Kölbl
Journal:  Strahlenther Onkol       Date:  2018-10       Impact factor: 3.621

3.  Robust Optimization for Intensity Modulated Proton Therapy Plans with Multi-Isocenter Large Fields.

Authors:  Li Liao; Gino J Lim; Yupeng Li; Juan Yu; Narayan Sahoo; Heng Li; Michael Gillin; X Ronald Zhu; Anita Mahajan; Steven J Frank; David R Grosshans; Quynh-Nhu Nguyen; Daniel Gomez; Xiaodong Zhang
Journal:  Int J Part Ther       Date:  2016-12-30

4.  Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma.

Authors:  Ellen D Yorke; Andrew Jackson; Li Cheng Kuo; Anthonia Ojo; Kelly Panchoo; Prasad Adusumilli; Marjorie G Zauderer; Valerie W Rusch; Annemarie Shepherd; Andreas Rimner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-27       Impact factor: 7.038

Review 5.  Proton beam therapy for malignant pleural mesothelioma.

Authors:  Shahed N Badiyan; Jason K Molitoris; Mingyao Zhu; Erica Glass; Tejan Diwanji; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2018-04

6.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

7.  Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma.

Authors:  Berrin Pehlivan; Kansu Sengul; Abdullah Yesil; Nilgul Nalbant; Osman Ozturk; Yurday Ozdemir; Erkan Topkan
Journal:  Biomed Res Int       Date:  2019-12-20       Impact factor: 3.411

Review 8.  Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.

Authors:  Fabio Nicolini; Martine Bocchini; Giuseppe Bronte; Angelo Delmonte; Massimo Guidoboni; Lucio Crinò; Massimiliano Mazza
Journal:  Front Oncol       Date:  2020-01-24       Impact factor: 6.244

Review 9.  Cardiotoxicity of mediastinal radiotherapy.

Authors:  Ivica Ratosa; Maja Ivanetic Pantar
Journal:  Rep Pract Oncol Radiother       Date:  2019-10-30

10.  Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy.

Authors:  Howard Lee; Jing Zeng; Stephen R Bowen; Ramesh Rengan
Journal:  Cureus       Date:  2017-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.